Clinical trials: Epilepsy Intractable
Epilepsies, Partial
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
- Trial name
- PROSPER1 (NCT00772603)
- Testing
- 2400mg SPN-804, 1200mg SPN-804
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 366 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
- Trial name
- NCT00368069
- Testing
- Keppra® extended release formulation - XR
- Where
- 34 sites in Brazil, Finland and 5 more
- Volunteers
- 158 people
- Sponsor
- UCB Pharma
Drug-resistant Epilepsy, Focal-Onset Seizures
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset…
- Trial name
- ARISE (NCT03373383)
- Testing
- Padsevonil
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 411 people
- Sponsor
- UCB Biopharma S.P.R.L.
Refractory Partial Seizures
An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
The purpose of this study is to explore the maximum tolerated dose of E2007 in Japanese patients with refractory partial seizures which are uncontrolled with other anti-epileptic drugs (AEDs).
- Trial name
- NCT00849212
- Testing
- E2007
- Where
- 9 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants…
- Trial name
- NCT02914314
- Testing
- perampanel
- Where
- 18 sites in United States, Latvia
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Epilepsy
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
- Trial name
- NCT00368472
- Testing
- Perampanel
- Where
- 47 sites in United States, Australia and 12 more
- Volunteers
- 138 people
- Sponsor
- Eisai Inc.
Seizures
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three…
- Trial name
- RESTORE1 (NCT00232596)
- Testing
- Retigabine
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
This is a randomized study designed to compare long-term treatment outcomes in pediatric patients with refractory seizures treated with VNS (Vagus Nerve Stimulation) Therapy versus anti-epileptic drugs (AEDs).
- Trial name
- NCT01118455
- Testing
- Vagus Nerve Stimulation (VNS) Therapy, Anti-Epileptic Drug (AED)
- Where
- 19 sites in Austria, Belgium and 3 more
- Volunteers
- 134 people
- Sponsor
- Cyberonics, Inc.
Partial Epilepsy
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy…
- Trial name
- NCT00957047
- Testing
- eslicarbazepine acetate, ESL - Part II
- Where
- Portugal
- Volunteers
- 395 people
- Sponsor
- Bial - Portela C S.A.
Epilepsies, Partial
Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
- Trial name
- NCT00918047
- Testing
- SPN-804O
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
A two arm, randomized, double-blind study comparing zonisamide with placebo. The zonisamide arm will consist of 100 subjects and the placebo arm of 50 subjects.
- Trial name
- NCT01546688
- Testing
- Zonisamide at targeted daily doses of 100-500 mg/day
- Where
- 36 sites in Germany, Hungary and 5 more
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Refractory Epilepsy
Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy.
- Trial name
- NCT02474407
- Testing
- diazepam nasal spray, diazepam rectal gel
- Where
- 22 sites in United States
- Volunteers
- 78 people
- Sponsor
- Acorda Therapeutics
Refractory Epilepsy
Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
The purpose of this observational registry is to evaluate the long-term effectiveness, safety and performance of market-released Medtronic Neuromodulation products for Deep Brain Stimulation (DBS) for the treatment of refractory…
- Trial name
- MORE (NCT01521754)
- Where
- 27 sites in Austria, Belgium and 11 more
- Volunteers
- 191 people
- Sponsor
- MedtronicNeuro
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard anti-epileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236860
- Testing
- topiramate
- Volunteers
- 56 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug Resistant Epilepsy
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
This is a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study with cross-over to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy
- Trial name
- NCT04714996
- Testing
- ES-481, Open-Label Extension Study
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- ES Therapeutics Australia Pty Ltd
Refractory Infantile Spasms
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.
- Trial name
- NCT03976076
- Testing
- JBPOS0101
- Where
- 23 sites in United States, South Korea
- Volunteers
- 16 people
- Sponsor
- Bio-Pharm Solutions Co., Ltd.
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Drug Resistant Epilepsy
A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl
This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.
- Trial name
- AURORA (NCT06340802)
- Testing
- VNS Treatment
- Where
- 2 sites in Belgium
- Volunteers
- 5 people
- Sponsor
- Synergia Medical
Epilepsy, Partial
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
To evaluate the safety and efficacy of levetiracetam used as adjunctive treatment in pediatric subjects age 1 month to less than 4 years with partial onset seizures.
- Trial name
- NCT00175890
- Testing
- Levetiracetam
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 116 people
- Sponsor
- UCB Pharma
Epilepsy
Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy
Research study to look for bio markers in epilepsy patients on ketogenic diet
- Trial name
- NCT04311242
- Testing
- Diet
- Where
- United States
- Sponsor
- Senda Biosciences